A share price of Editas Medicine Inc [EDIT] is currently trading at $1.28, up 0.79%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EDIT shares have gain 15.32% over the last week, with a monthly amount drifted -7.91%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on December 16, 2024, when JP Morgan downgraded its rating to a Underweight. Previously, Truist downgraded its rating to Hold on December 13, 2024. On December 13, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $3 on the stock. Chardan Capital Markets downgraded its rating to a Neutral. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $4 on December 11, 2024. BofA Securities downgraded its rating to Underperform for this stock on November 25, 2024, and downed its price target to $1. In a note dated November 06, 2024, Evercore ISI upgraded an Outperform rating on this stock.
Editas Medicine Inc experienced fluctuations in its stock price throughout the past year between $0.91 and $6.69. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $1.28 at the most recent close of the market. An investor can expect a potential return of 525.0% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
Trailing Twelve Months sales for Editas Medicine Inc [NASDAQ:EDIT] were 32.31M which represents -49.03% decline. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -7.77%, Pretax Profit Margin comes in at -7.34%, and Net Profit Margin reading is -7.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.69, Equity is -1.13 and Total Capital is -0.95. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2514 points at the first support level, and at 1.2227 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3073, and for the 2nd resistance point, it is at 1.3345.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Editas Medicine Inc [NASDAQ:EDIT] is 3.75. Further, the Quick Ratio stands at 3.75, while the Cash Ratio is 1.7. Considering the valuation of this stock, the price to sales ratio is 3.32, the price to book ratio is 0.79.
Transactions by insiders
Recent insider trading involved Lucera Erick, EVP, CHIEF FINANCIAL OFFICER, that happened on Mar 04 ’25 when 4109.0 shares were sold. CEO, O’Neill Gilmore Neil completed a deal on Mar 04 ’25 to sell 16632.0 shares. Meanwhile, EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold 2891.0 shares on Mar 04 ’25.
